Extended Data Fig. 2: BBB breakdown in the HC and PHG in APOE4 carriers increases with cognitive domain impairment.
From: APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline
a, b, Ktrans constant in the HC (a) and PHG (b) in individuals with no cognitive domains impaired bearing APOE3 (black, n = 70) or APOE4 (red, n = 40); one cognitive domain impaired bearing APOE3 (n = 18) or APOE4 (n = 21); and two or more cognitive domains impaired bearing APOE3 (n = 7) or APOE4 (n = 12). Continuous lines, median; dotted lines, IQR. c, d, Ktrans (estimated marginal mean ± s.e.m.from ANCOVA models corrected for age, sex, education, CSF Aβ1–42 and pTau status, and HC and PHG volumes) in the HC (c) and PHG (d) in individuals with no cognitive domains impaired bearing APOE3 (n = 70) or APOE4 (n = 40); one cognitive domain impaired bearing APOE3 (n = 18) or APOE4 (n = 21); and two or more cognitive domains impaired bearing APOE3 (n = 7) or APOE4 (n = 12). Significance by ANCOVA for main effects and post hoc comparisons controlling for age, sex, and education. All ANCOVA omnibus tests remained significant at FDR threshold of 0.05.
